Nothing Special   »   [go: up one dir, main page]

BRPI0508170A - formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem - Google Patents

formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem

Info

Publication number
BRPI0508170A
BRPI0508170A BRPI0508170-0A BRPI0508170A BRPI0508170A BR PI0508170 A BRPI0508170 A BR PI0508170A BR PI0508170 A BRPI0508170 A BR PI0508170A BR PI0508170 A BRPI0508170 A BR PI0508170A
Authority
BR
Brazil
Prior art keywords
active ingredient
dry powder
low dose
pharmaceutical formulations
powder inhalers
Prior art date
Application number
BRPI0508170-0A
Other languages
English (en)
Inventor
Roberto Bilzi
Angela Armanni
Roberto Rastelli
Daniela Cocconi
Rossella Musa
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of BRPI0508170A publication Critical patent/BRPI0508170A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçõES FARMACêUTICAS PARA INALADORES DE Pó SECO, QUE COMPREENDEM UM INGREDIENTE ATIVO DE POTêNCIA DE BAIXA DOSAGEM A invenção proporciona uma formulação a ser administrada como pó seco para inalação, adequado para administração eficaz de ingredientes ativos de potência de baixa dosagem no trato respiratório inferior de pacientes. Particularmente, a invenção proporciona uma formulação que compreende micropartículas constituídas, por sua vez, de micropartículas de ingrediente ativo de potência de baixa dosagem e micropartículas de um excipiente, em que o MMD destas está compreendido entre 2 e micrómetros e pelo menos 10% delas possuem um diâmetro de massa (MD) maior que 0,5 micrómetro, o processo de preparação dessa formulação.
BRPI0508170-0A 2004-03-17 2005-03-16 formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem BRPI0508170A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04006430 2004-03-17
PCT/EP2005/002789 WO2005089717A1 (en) 2004-03-17 2005-03-16 Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient

Publications (1)

Publication Number Publication Date
BRPI0508170A true BRPI0508170A (pt) 2007-08-07

Family

ID=34962706

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508170-0A BRPI0508170A (pt) 2004-03-17 2005-03-16 formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem

Country Status (20)

Country Link
US (1) US8153104B2 (pt)
EP (1) EP1729728B1 (pt)
KR (1) KR20060130216A (pt)
CN (1) CN1942172B (pt)
AR (1) AR049010A1 (pt)
AU (1) AU2005224008B2 (pt)
BR (1) BRPI0508170A (pt)
CA (1) CA2560226C (pt)
ES (1) ES2566618T3 (pt)
HK (1) HK1101346A1 (pt)
JO (1) JO3102B1 (pt)
MA (1) MA28514B1 (pt)
MX (1) MXPA06010593A (pt)
NO (1) NO342481B1 (pt)
NZ (1) NZ549870A (pt)
PE (1) PE20060716A1 (pt)
RU (1) RU2371171C2 (pt)
TN (1) TNSN06277A1 (pt)
WO (1) WO2005089717A1 (pt)
ZA (1) ZA200607700B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
US20100063016A1 (en) * 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
US8962063B2 (en) * 2009-08-27 2015-02-24 St.Unm Methods and systems for dosing and coating inhalation powders onto carrier particles
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
JP5927175B2 (ja) * 2010-04-01 2016-06-01 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ドライパウダー状の吸入用医薬組成物、担体粒子および医薬品の製造方法
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
RS63706B1 (sr) * 2012-01-25 2022-11-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
CN104703584B (zh) * 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
JP5087182B1 (ja) * 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
MX2015012931A (es) * 2013-03-13 2016-07-20 Forest Lab Holdings Ltd Composiciones farmaceuticas micronizadas.
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP6426167B2 (ja) 2013-07-11 2018-11-21 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗コリン作用薬、副腎皮質ステロイドおよびβアドレナリン作動薬を含む吸入投与用乾燥粉末製剤
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
PL3191081T3 (pl) 2014-09-09 2020-09-07 Vectura Limited Formulacja zawierająca glikopirolan, sposób i urządzenie
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
KR20220114042A (ko) * 2019-12-16 2022-08-17 씨젠 인크. 부형제의 고성능 액체 크로마토그래피 정량 방법
WO2021236570A1 (en) * 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441740B1 (de) 1990-01-29 1993-09-22 Ciba-Geigy Ag Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
MXPA03001092A (es) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US6587025B2 (en) * 2001-01-31 2003-07-01 Vishay Dale Electronics, Inc. Side-by-side coil inductor
JP2009513531A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug

Also Published As

Publication number Publication date
ES2566618T3 (es) 2016-04-14
CA2560226C (en) 2013-07-23
MA28514B1 (fr) 2007-04-03
CN1942172B (zh) 2010-10-06
WO2005089717A1 (en) 2005-09-29
CA2560226A1 (en) 2005-09-29
NO20064161L (no) 2006-10-17
US20070202053A1 (en) 2007-08-30
CN1942172A (zh) 2007-04-04
AU2005224008B2 (en) 2010-09-16
AR049010A1 (es) 2006-06-21
EP1729728A1 (en) 2006-12-13
US8153104B2 (en) 2012-04-10
EP1729728B1 (en) 2016-03-16
HK1101346A1 (en) 2007-10-18
RU2006133038A (ru) 2008-03-20
AU2005224008A1 (en) 2005-09-29
JO3102B1 (ar) 2017-09-20
KR20060130216A (ko) 2006-12-18
NO342481B1 (no) 2018-05-28
ZA200607700B (en) 2008-05-28
NZ549870A (en) 2010-05-28
MXPA06010593A (es) 2007-02-16
PE20060716A1 (es) 2006-07-25
RU2371171C2 (ru) 2009-10-27
TNSN06277A1 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
MA26892A1 (fr) Formulations pharmaceutiques sous forme de comprimes pour inhalateurs a parer
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
ATE400313T1 (de) Verbessertes trockenpulver-inhalationssystem
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
MXPA05009629A (es) Composiciones que contienen trospio.
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
Balducci et al. Drug delivery strategies for pulmonary administration of antibiotics
BR0308984A (pt) Formulações em pó adequadas para inalação
CR10261A (es) Formulaciones novedosas
CA2456721A1 (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
TH75699B (th) สูตรผสมทางเภสัชกรรมสำหรับเครื่องพ่นยาผงแห้ง ซึ่งประกอบรวมด้วยส่วนประกอบออกฤทธิ์ที่มีความแรงของขนาดยาต่ำ
TH75699A (th) สูตรผสมทางเภสัชกรรมสำหรับเครื่องพ่นยาผงแห้ง ซึ่งประกอบรวมด้วยส่วนประกอบออกฤทธิ์ที่มีความแรงของขนาดยาต่ำ

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]